Inhibitory effect of PPARγ agonist on the proliferation of human pterygium fibroblasts

Abstract

The effects of DK2, a peroxisome proliferator-activated receptor γ agonist, on cultured human pterygium fibroblasts (HPFs) in virto were studied. The HPFs were incubated with 0–200 μmol/L DK2 for 12–72 h. The MTT method was used to assay the bio-activity of DK2 at different doses and time. The cytotoxic effect of DK2 was measured by LDH release assay. The cell cycle distribution and apoptosis were flow cytometrically detected. The expression of proliferating cell nuclear antigen (PCNA) in each group was detected by real-time PCR (RT-PCR) and Western blotting. The results showed that administration of 1–75 μmol/L DK2 for 12–72 h could significantly inhibit HPF proliferation in a dose- and time-dependent manner. DK2-treated cells did not release significant amount of LDH as compared with rosiglitazone-treated cells. After treatment with DK2 at concentrations of 15, 25 μmol/L for 24 h, the number of HPFs in G₀/G₁ phase was significantly increased while that in S phase was significantly decreased (P<0.05), leading to arrest at G₀/G₁ phase. The apoptosis rates of HPF cells in drug-treated groups were significantly higher than the rate of control group (P<0.05). At the dosage range between 15–25 μmol/L, DK2 could inhibit the expression of PCNA mRNA and protein in HPFs in a dose-dependent fashion (P<0.05). It was concluded that PPARγ agonist can significantly inhibit HPF proliferation, resulting in the arrest at G₀/G₁ phase, induce the apoptosis of HPFs, and suppress the synthesis of PCNA, in dose- and time-dependent manners.

Keywords

DK2 / peroxisome proliferator-activated receptor γ / pterygium / human pterygium fibroblasts / proliferation / inhibition

References

[1] MauroJ., FosterC.S.. Pterygia: pathogenesis and the role of subconjunctival bevacizumab intreatment. Semin Ophthalmol, 2009, 24(3): 130-134

[2] Yalcin TokO., Burcu NurozierA., ErgunG., et al.. Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica, 2008, 222(6): 391-396

[3] MichalikL., WahliW.. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest, 2006, 116(3): 598-606

[4] LiY., WenX., SpataroB.C., et al.. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator activated receptor-γ agonists. J Am Soc Nephrol, 2006, 17(1): 54-65

[5] XiongX., YeY., FuL., et al.. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines. Invest New Drugs, 2009, 27(3): 223-232

[6] SolomonA., LiD.Q., LeeS.B., et al.. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci, 2000, 41(8): 2154-2163

[7] DushkuN., ReidT.W.. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res, 1994, 13(7): 473-481

[8] KriaL., OhiraA., AmemiyaT.. Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol, 1998, 236(9): 702-708

[9] TassyA., RibeD.. Thiotepa eyedrops for prevention of pterygium recurrence: 18 years of use. J Fr Ophtalmol, 1999, 22(2): 215-219

[10] ViveirosM.M., SchelliniS.A., CandeiasJ., et al.. Exposure of normal Tenon’s capsule fibroblasts from pterygium to 5-fluorouracil and Mitomycin C. Arq Bras Oftalmol, 2007, 70(1): 73-77

[11] ValeziV.G., SchelliniS.A., ViveirosM.M., et al.. Safety and efficacy of intraoperative 5-fluorouracil infiltration in pterygium treatment. Arq Bras Oftalmol, 2009, 72(2): 169-173

[12] LeeJ.S., OumB.S., LeeS.H.. Mitomycin C influence on inhibition of cellular proliferation and subsequent synthesis of type I collagen and laminin in primary and recurrent pterygia. Ophthalmic Res, 2001, 33(3): 140-146

[13] DonnenfeldE.D., PerryH.D., FromerS., et al.. Subconjunctival mitomycin C as adjunctive therapy before pterygium excision. Ophthalmology, 2003, 110(5): 1012-1016

[14] OguzH., BasarE., GurlerB.. Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery. Acta Ophthalmol Scand, 1999, 77(2): 147-150

[15] DunnJ.P., SeamoneC.D., OstlerH.B., et al.. Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy. Am J Ophthalmol, 1991, 112(3): 343-344

[16] RubinfeldR.S., PfisterR.R., SteinR.M., et al.. Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology, 1992, 99(11): 1647-1654

[17] RosenfeldP.J., MoshfeghiA.A., PuliafitoC.A., et al.. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthal Surg Lasers Imaging, 2005, 36(4): 331-335

[18] SpaideR.F., FisherY.L.. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina, 2006, 26(3): 275-278

[19] MansourA.M.. Treatment of inflamed or residual pterygial bed. Br J Ophthalmol, 2009, 93(7): 864-865

[20] ZhangM.C., BianF., WenC., et al.. Inhibitory effect of curcumin on proliferation of human pterygium fibroblasts. J Huazhong Univ Sci Technol [Med Sci], 2007, 27(3): 339-342

[21] Di GirolamoN., ChuiJ., CoroneoM.T., et al.. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res, 2004, 23(2): 195-228

[22] JinJ., GuanM., SimaJ., et al.. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea, 2003, 22(5): 473-477

[23] Di GirolamoN., WakefieldD., CoroneoM.T.. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci, 2006, 47(6): 2430-2437

[24] VignatiS., AlbertiniV., RinaldiA., et al.. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia, 2006, 8(10): 851-861

[25] YangL., ChanC.C., KwonO.S., et al.. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol, 2006, 291(5): 902-911

[26] GurnellM.. ’striking the Right Balance’ in Targeting PPARγ in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. PPAR Res, 2007, 2007: 83593

[27] OhtaY., IchimuraK.. Proliferation markers, proliferating cell nuclear antigen, Ki67, 5-bromo-2′-deoxyuridine, and cyclin D1 in mouse olfactory epithelium. Ann Otol Rhinol Laryngol, 2000, 109(11): 1046-1048